Not Signed In -
Fludarabine Phosphate |
Fludara |
Clinical Trial: A Study of an Investigational Study Drug for Type 2 Diabetes Mellitus
This study is currently recruiting patients.
Verified by Merck August 2005
|
Purpose
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type2 diabetes Mellitus
| Condition | Intervention | Phase |
|---|---|---|
| Type2 Diabetes Mellitus | Drug: MK0431, sitagliptin phosphate | Phase II |
MedlinePlus related topics: Diabetes
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 20 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients with Type2 Diabetes Mellitus
Exclusion Criteria:
- Patients with Type1 Diabetes Mellitus
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00127192
Call For Information +81-3-5203-8218
Japan, Chuoku
Call For Site Information, Tokyo, Chuoku, 103-8416, Japan; Recruiting
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_037
Last Updated: August 22, 2005
Record first received: August 3, 2005
ClinicalTrials.gov Identifier: NCT00127192
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 22, 2005
Record first received: August 3, 2005
ClinicalTrials.gov Identifier: NCT00127192
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Fludara (Drug Digest)
- Fludarabine Phosphate (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
